Aspirin for cardiovascular prevention in patients with diabetes
Ogawa H et al. – Low-dose aspirin use was associated with a non-statistically significant 20% reduction in atherosclerotic events among Japanese adults with type 2 diabetes. Further study with a larger sample size must confirm these findings. Methods- Multicenter, randomized trial of 2,539 Japanese pts with type 2 diabetes and no history of atherosclerotic disease
- Subjects age 30-85 yrs; mean age: 65 yrs; ~ 45% female
- Randomization to low-dose aspirin or no aspirin in open-label design
- Primary outcome: any atherosclerotic event
- Atherosclerotic event defined as cardiovascular death, nonfatal myocardial infarction, unstable angina, new-onset stable angina, stroke (ischemic or hemorrhagic), transient ischemic attack, or new peripheral vascular disease
- Adjudication of all outcomes by an independent committee blinded to intervention status
- Median follow-up: 4.37 yrs (193 of 2,539 lost follow-up)
Results- Aspirin use was associated with a nonstatistically significant reduction in the incidence of the primary outcome: 13.6/1,000 pt-yrs for aspirin group and 17.0/1,000 pt-yrs for controls
- Fewer fatal events with aspirin use; these outcomes were uncommon
- Hemorrhagic stroke, gastrointestinal bleeding, and ulcers more common with aspirin group; differences not statistically significant
[more...]
|
|
|
